Dwindling COVID-19 Test Demand Forces LumiraDx Cut SPAC Deal Value
Benzinga
Aug 21, 2021
Fall in demand for COVID-19 screening has led LumiraDx to slash $2 billion off the value of a planned reverse merger with a special purpose acquisition company (SPAC).
See:LumiraDx Withdraws $100M IPO In Favor Of $5B SPAC Merger.
First announced in April, the U.K.-based diagnostics company aimed to debut on NASDAQ with the blank-check firm CA Healthcare Acquisition Corp (NASDAQ:CAHC) and had charted out a $5 billion pro forma enterprise value for the combination.
Now LumiraDx is knocking 40% off that projected valuation while also saying that the market environment for publicly traded diagnostic companies has changed and is following feedback from the SPAC’s advisors and shareholders.
LumiraDx also reduced its revenue guidance for 2021, from the $600 million to $1 billion it had been forecasting in April, down to $300 million to $500 million by the end of this year.
Related:LumiraDX COVID-19 Antibody Test Received FDA Emergency Use Nod.
Price Action: CAHC shares are up 0.29% at $9.90 during the market session on the last check Friday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.